CyberKnife market seen reaching $1.56 billion by 2030

The Business Research Company says the CyberKnife market will grow from $0.72 billion in 2025 to $1.56 billion by 2030, driven by cancer incidence, minimally invasive care and more precision oncology investment. North America held the largest share in 2025 as robotic radiosurgery and AI-assisted planning gain traction.

Why it matters: - CyberKnife is positioned as a less invasive option for treating malignant and benign tumors, which matters as cancer cases rise and patients seek treatments with fewer side effects. - The market forecast points to expanding demand for robotic radiosurgery, image-guided therapy and precision oncology tools over the rest of the decade.

What happened: - The Business Research Company released a CyberKnife market outlook on Aug. 3, 2026, from London. - The report estimates the market will rise from $0.72 billion in 2025 to $0.84 billion in 2026. - The report projects the market will reach $1.56 billion by 2030. - The forecast implies a 16.4% CAGR in the 2025-2026 period and a 16.6% CAGR through 2030. - North America held the largest share of the CyberKnife market in 2025.

The details: - CyberKnife treatment uses smaller margins around tumors, which reduces radiation exposure to healthy tissue. - The system is designed for malignant tumors, benign tumors and other conditions where radiation therapy is appropriate. - Growth drivers in the historical period include rising cancer cases, more radiation oncology facilities, wider use of stereotactic radiosurgery, better treatment-planning software and improved robotic medical technology. - Forecast drivers include higher investment in precision oncology, more outpatient cancer treatment demand, more advanced cancer care centers, greater use of artificial intelligence in radiation planning and stronger focus on patient-specific therapy optimization. - The report flags wider use of robotic radiosurgery systems, more image-guided radiation therapy, more demand for non-invasive tumor treatment, growth in precision radiation platforms and greater focus on treatment accuracy and patient safety. - The market coverage includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The company added new analytical features to its 2026 market reports, including market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel forecasting dashboards, market hotspots infographics and updated charts and tables. - The report offers a free sample here. - The full report is available here.

Between the lines: - The report ties CyberKnife demand to the broader shift toward minimally invasive care, which has become more attractive because it can reduce complications and speed recovery. - The cited growth in minimally invasive procedures suggests the market tailwind is not just about oncology technology, but about a broader preference change in how patients and physicians approach treatment. - The reference to AI in radiation planning suggests competitive pressure is shifting toward workflow precision and personalization, not just hardware capability.

What's next: - The market is expected to keep expanding through 2030 if precision oncology investment and outpatient cancer care continue to rise. - Adoption of robotic radiosurgery and AI-assisted planning will likely be key markers to watch across major regions. - North America is expected to remain influential, while other regions show additional growth potential.